Contraceptive vaginal ring effectiveness is maintained during 6 weeks of use: A prospective study of normal BMI and obese women

Contraception

Volumn 87, Issue 4, 2013, Pages 432-436

  Dragoman, Monica ^a   Petrie, Kelsey ^b   Torgal, Anupama ^c   Thomas, Tiffany ^c   Cremers, Serge ^c   Westhoff, Carolyn L ^c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Columbia University ^*  (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Contraceptive vaginal ring; Obesity; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ETHINYLESTRADIOL; ETONOGESTREL; PROGESTERONE;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; ENDOMETRIAL THICKNESS; FEMALE; FOLLOW UP; HORMONE BLOOD LEVEL; HUMAN; OBESITY; OPEN STUDY; OVARY FOLLICLE; PROGESTERONE BLOOD LEVEL; PROSPECTIVE STUDY; SPOTTING; THERAPY EFFECT; TREATMENT DURATION; VAGINA RING;

ADULT; BODY MASS INDEX; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVE DEVICES, FEMALE; DESOGESTREL; ETHINYL ESTRADIOL; FEMALE; HUMANS; OBESITY; OVARIAN FOLLICLE; PROSPECTIVE STUDIES; VAGINA; YOUNG ADULT;

EID: 84875275501     PISSN: 00107824     EISSN: 18790518     Source Type: Journal    
DOI: 10.1016/j.contraception.2012.12.001     Document Type: Article

References (16)

1. Nuvaring® [package insert]. Roseland, NJ: Organon, a subsidiary of Merck & Co., Inc; 2001, 2010.
2. J.J. Frost, J.E. Darroch, and L. Remez Improving contraceptive use in the United States, in brief 2008 Guttmacher Institute New York No. 1
3. H.J. Ahrendt, I. Nisand, and C. Bastianelli Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 mcg of ethinyl estradiol and 3 mg of drospirenone Contraception 74 2006 451 457
4. K. Oddsson, B. Leifels-Fischer, and N. de Melo Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial Contraception 71 2005 176 182
5. F. Roumen, M. op ten Berg, and E. Hoomans The combined contraceptive vaginal ring (NuvaRing): first experience in daily clinical practice in The Netherlands Eur J Contracept Reprod Health Care 11 2006 14 22
6. C. Timmer, and T. Mulders Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring Clin Pharmacokinet 39 2000 233 242
7. M.A. McDowell, C.D. Fryar, C.L. Ogden, and K.M. Flegal Anthropometric reference data for children and adults: United States, 2003-2006. National health statistics reports; no 10 2008 National Center for Health Statistics Hyattsville, MD
8. C.L. Westhoff, A.H. Torgal, and E.R. Mayeda Pharmacokinetics and ovarian suppression during use of a contraceptive vaginal ring in normal weight and obese women Am J Obstet Gynecol 207 2012 39 45
9. C.L. Westhoff, A.H. Torgal, and E.R. Mayeda Ovarian suppression in normal weight and obese women during oral contraceptive use: a randomized controlled trial Obstet Gynecol 116 2010 275 283
10. World Health Organization Department of Reproductive Health and Research Medical eligibility criteria for contraceptive use 4th ed. 2010 World Health Organization Geneva
11. T. Mulders, and T. Dieben Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition Fertil Steril 75 2001 865 870
12. H.J. Coelingh Bennink The pharmacokinetics and pharmacodynamics of Implanon®, a single-rod etonogestrel contraceptive implant Eur J Contracept Reprod Health Care 5 Suppl. 2 2000 12 20
13. S.E. Olsson, V. Odlind, and E. Johanssen Clinical results with subcutaneous implants containing 3-ketodesogestrel Contraception 42 1990 1 11
14. S. Diaz, M. Pavez, and A.J. Moo-Young Clinical trial with 3-keto-desogestrel subdermal implants Contraception 44 1991 393 408
15. L.M.D. Miller, C.H.J.P. Verhoeven, and M.S. Hout Jit Extended regimens of the contraceptive vaginal ring: a randomized trial Obstet Gynecol 106 2005 473 482
16. F.A. Barrieros, C.A.F. Guazzelli, R. Barbosa, F. de Assis, and F. Fernando de Araujo Extended regimens of the CVR- evaluation of clinical aspects Contraception 81 2010 223 225